[
1.HINDRICKS, G., POTPARA, T., DAGRES, N., ARBELO, E., BAX, J.J., BLOMSTRÖM-LUNDQVIST, C., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European. Eur. Heart J. 2020;
]Search in Google Scholar
[
2.HINDRICKS, G., POTPARA, T., DAGRES, N., BAX, J.J., BORIANI, G., DAN, G.A., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2021;42(5):373–49810.1093/eurheartj/ehaa61232860505
]Search in Google Scholar
[
3.GYH, L. The ABC pathway: an integrated approach to improve AF management. Nat. Rev. Cardiol. 2017;14(11):627–628
]Search in Google Scholar
[
4.SINGER, D.E., CHANG, Y., BOROWSKY, L.H., FANG, M.C., POMERNACKI, N.K., UDALTSOVA, N., et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: The ATRIA study stroke risk score. J. Am. Heart Assoc. 2013;2(3)10.1161/JAHA.113.000250369879223782923
]Search in Google Scholar
[
5.HIJAZI, Z., LINDBÄCK, J., ALEXANDER, J.H., HANNA, M., HELD, C., HYLEK, E.M., et al. The ABC (age, biomarkers, clinical history) stroke risk score: A biomarker-based risk score for predicting stroke in atrial fibrillation. Eur. Heart J. 2016;37(20):1582–159010.1093/eurheartj/ehw054487556026920728
]Search in Google Scholar
[
6.DALGAARD, F., PIEPER, K., VERHEUGT, F., CAMM, A.J., FOX, K.A.A., KAKKAR, A.K., et al. GARFIELD-AF model for prediction of stroke and major bleeding in atrial fibrillation: A Danish nationwide validation study. BMJ Open 2019;9(11)10.1136/bmjopen-2019-033283685825031719095
]Search in Google Scholar
[
7.ROLDÁN, V., MARÍN, F., FERNÁNDEZ, H., MANZANO-FERNÁNDEZ, S., GALLEGO, P., VALDÉS, M., et al. Renal impairment in a ‘real-life’ cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am. J. Cardiol. 2013;111(8):1159–116410.1016/j.amjcard.2012.12.04523337836
]Search in Google Scholar
[
8.BLOMSTROM LUNDQVIST, C., LIP, G.Y.H., KIRCHHOF, P. What are the costs of atrial fibrillation?. Europace 2011;13(SUPPL. 2):9–1210.1093/europace/eur08721518753
]Search in Google Scholar
[
9.FOX, K.A.A., LUCAS, J.E., PIEPER, K.S., BASSAND, J.P., CAMM, A.J., FITZMAURICE, D.A., et al. Improved risk stratification of patients with atrial fibrillation: An integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open 2017;7(12):1–1110.1136/bmjopen-2017-017157577833929273652
]Search in Google Scholar
[
10.LIP, G.Y.H., NIEUWLAAT, R., PISTERS, R., LANE, D.A., CRIJNS, H.J.G.M., ANDRESEN, D., et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest 2010;137(2):263–27210.1378/chest.09-158419762550
]Search in Google Scholar
[
11.FRIBERG, L., ROSENQVIST, M., LIP, G.Y.H. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: The Swedish Atrial Fibrillation cohort study. Eur. Heart J. 2012;33(12):1500–151010.1093/eurheartj/ehr48822246443
]Search in Google Scholar
[
12.APOSTOLAKIS, S., LANE, D.A., BULLER, H., LIP, G.Y.H. Comparison of the CHADS2, CHA2DS2 -VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: The AMADEUS trial. Thromb. Haemost. 2013;110(5):1074–107910.1160/TH13-07-055224048467
]Search in Google Scholar
[
13.PUURUNEN, M.K., KIVINIEMI, T., SCHLITT, A., RUBBOLI, A., DIETRICH, B., KARJALAINEN, P., et al. CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention. Thromb. Res. 2014;133(4):560–566
]Search in Google Scholar
[
14.OLDGREN, J., ALINGS, M., DARIUS, H., DIENER, H.C., EIKELBOOM, J., EZEKOWITZ, M.D., et al. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: A subgroup analysis of the Re-Ly trial. Ann. Intern. Med. 2011;155(10):660–667
]Search in Google Scholar
[
15.FU, S., ZHOU, S., LUO, L., YE, P. Clinical Interventions in Aging Dovepress r 2(gFr) ChADs 2 and r 2(gFr) ChA 2 Ds 2 VAsc schemes improved the performance of ChADs 2 and ChA 2 Ds 2 VASc scores in death risk stratification of Chinese older patients with atrial fibrillation. Clin. Interv. Aging 2017;12–123310.2147/CIA.S138405555710528848331
]Search in Google Scholar
[
16.APIYASAWAT, S., TANGCHAROEN, T., WISARATAPONG, T., YAMWONG, S., WIBOONPOLPRASERT, S., SRITARA, P. CHA2DS2-VASc scores predict mortality after hospitalization for atrial fibrillation. Int. J. Cardiol. 2015;185:293–296
]Search in Google Scholar
[
17.JOVER, E., ROLDÁN, V., GALLEGO, P. Predictive Value of the CHA2DS2-VASc Score in Atrial Fibrillation Patients at High Risk for Stroke Despite Oral Anticoagulation. Rev Esp Cardiol (Engl Ed) 2012;65(7):627–63310.1016/j.recesp.2012.02.01722609214
]Search in Google Scholar
[
18.MAEHAMA, T., OKURA, H., IMAI, K., YAMADA, R., OBASE, K., SAITO, K., et al. Usefulness of CHADS2 score to predict C-reactive protein, left atrial blood stasis, and prognosis in patients with nonrheumatic atrial fibrillation. Am. J. Cardiol. 2010;106(4):535–53810.1016/j.amjcard.2010.03.06720691312
]Search in Google Scholar
[
19.CAMELO-CASTILLO, A., RIVERA-CARAVACA, J.M., MARÍN, F., VICENTE, V., LIP, G.Y.H., ROLDÁN, V. Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project. Thromb. Haemost. 202010.1055/s-0040-171291432506417
]Search in Google Scholar
